Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline is planning to start Phase 2 studies of selective JAK1 molecule, GSK2586184, to treat two auto-immune disorders systemic lupus erythematosus (SLE) and chronic plaque psoriasis.
Subscribe to our email newsletter
GSK is expecting to assess the safety and efficacy profile of varying doses of GSK2586184 in a multi-center placebo-controlled Phase 2 study scheduled for 12 weeks, in SLE patients.
Another multi-center placebo-controlled Phase 2 study of GSK2586184 will also be conducted to evaluate efficacy and safety of the candidate in chronic plaque psoriasis patients.
Galapagos CEO Onno van de Stolpe said, "With two of our JAK1 molecules in Phase 2, we hope that this will deliver a new class of medicines to patients with inflammatory diseases."
GSK2586184, which was discovered and developed under Galapagos’ osteoarthritis alliance with GSK, will be the second selective JAK1 molecule discovered by Galapagos to enter Phase 2 studies.
Galapagos is eligible for €34m in additional milestones in addition to sales based royalties of all therapeutic indications of GSK2586184.